Key clinical trials of valemetostat
| Drug(s) | Indication | Phase | Status | Location(s) | Sponsor/Collaborator | Identifier |
|---|---|---|---|---|---|---|
| Valemetostat | R/R ATL | 2 | Ongoing | Japan | Daiichi Sankyo | NCT04102150; JapicCTI-194964 |
| Valemetostat | R/R PTCL | 2 | Ongoing | Global | Daiichi Sankyo | NCT04703192; EudraCT2020-004954-31; jRCT2071200095; VALENTINE-PTCL01 |
| Valemetostat | R/R NHL (including BCL, ATL and PTCL) | 1 | Ongoing | Japan, USA | Daiichi Sankyo | NCT02732275; JapicCTI-163173 |
| Valemetostat | R/R BCL | 2 | Ongoing | Belgium, France | The Lymphoma Academic Research Organisation; Daiichi Sankyo | NCT04842877; EudraCT2020-005225-81; VALYM |
| Valemetostat | AML or ALL | 1 | Terminateda | USA | Daiichi Sankyo | NCT03110354 |
| Valemetostat, irinotecan | Recurrent SCLC | 1/2 | Ongoing | USA | Memorial Sloan Kettering Cancer Center | NCT03879798 |
| Valemetostat, ipilimumab | Metastatic prostate, urothelial, and renal cell cancers | 1 | Ongoing | USA | M.D. Anderson Cancer Center; National Cancer Institute | NCT04388852; NCI-2020-02916 |
| Valemetostat | Malignant solid tumoursb | 1 | Ongoing | Japan | National Cancer Center Hospital, Tokyo |
jRCT2031190268 NCCH1904/MK007; ELEPHANT |
AML acute myelogenous leukaemia, ALL acute lymphocytic leukaemia, ATL adult T-cell leukaemia/lymphoma, BCL B-cell lymphoma, NHL non-Hodgkin lymphoma, PTCL peripheral T-cell lymphoma, R/R relapsed/refractory, SCLC small cell lung cancer
aTerminated because of slow patient accrual
bIn children, adolescents and young adults aged 3–29 years